Amgen

Open: 233.77 Close: 234.82 Change: 1.05

Don't invest before reading what an AI found about Amgen.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, AMGN, Health, Care, sector, industry, Therapeutics, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen closed at $218.65, marking a -1.94% move from the previous day. Amgen shareholders have earned a 5.8% CAGR. Telos Capital Management Inc. acquired a new stake. Settlement talks have ended between the Federal Trade Commission and Amgen over the proposed acquisition of Horizon Therapeutics. FTC first filed its lawsuit in May 2023, seeking to block Amgen.

Today's News

Amgen has already reduced its drug development timelines by about three years. Amgen scientists are applying speed levers in multiple areas, from digital technology and innovative study designs. Amgen Inc. (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session. The complex U.S. healthcare system often results in higher costs for patients. Amgen (AMGN) Dips More Than Broader Markets: What You Should Know in the latest trading session, Amgen closed at $218.65, marking a -1.94% move from the previous day. Amgen shareholders have earned a 5.8% CAGR. The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck. Telos Capital Management Inc. acquired a new stake in Amgen during the fourth quarter. Currently, hedge funds and other institutional investors own approximately 74.70% of Amgens stock. Amgen Inc. (NASDAQ: AMGN) Investors urged to secure Counsel before important May 12 Deadline in Securities Class Action. Amgen (NASDAQ:AMGN) is in the Health Care sector and Biotechnology industry. Q2 earnings are confirmed for Thursday, August 3, 2023. There is no upcoming split for Amgen. Amgen (AMGN) Stock Getting a Bullish Rating. Barclays sticks to its Sell Rating for Amgen. Amgen (NASDAQ:AMGN), Quotes and News Summary Amgen stock price, news, charts, charts and stock research, profile. Amgen is in the Health Care sector and Biotechnology industry. Amgen, FTC said there are no ongoing talks to settle over Horizon Therapeutics deal. Barclays Sticks to its Sell Rating for Amgen (AMGN) TipRanks: Amgen gets a Hold from RBC Capital. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in CrohAN THERERON THERON. Amgen (NASDAQ:AMGN) is in the Health Care sector and Biotechnology industry. Q2 earnings are confirmed for Thursday, August 3, 2023. There is no upcoming split for Amgen. Amgen, FTC said there are no ongoing talks to settle over Horizon Therapeutics deal. Barclays sticks to its Sell Rating for Amgen (AMGN) TipRanks. Amgen (NASDAQ:AMGN) stock price is $ 234.82 last updated July 21, 2023 at 8:00 PM UTC. Amgen is in the Health Care sector and Biotechnology industry. Amgen (NASDAQ:AMGN) stock is $ 234.82 last updated July 21, 2023 at 8:00 PM UTC. Amgen is in the Health Care sector and industry Amgen operates in. There is no upcoming split for Amgen. Amgen, FTC said there are no ongoing talks to settle over Horizon Therapeutics deal. Amgen (NASDAQ:AMGN) is in the Health Care sector and Biotechnology industry. Amgens Q2 earnings are confirmed for Thursday, August 3, 2023. There is no upcoming split for Amgen. Amgen, FTC said there are no ongoing talks to settle over Horizon Therapeutics deal. Barclays Sticks to its Sell Rating for Amgen (AMGN) TipRanks: Amgen gets a Hold from RBC Capital. Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in CrohAN THERON THERERON. Amgen is in the Health Care sector and Biotechnology industry. Amgen pays a quarterly cash dividend of $ 2.13 per share of Class A Common Stock. Other companies in Amgens space include Legend Biotech (NASDAQ : LEGN ) , Exact Sciences ( NASDAQ : EXAS ) , Sarepta Therapeutics ( NASdaq : SRPT ) , Neurocrine Chemisyisma strategist parach inscribed [| ban appearddsVariableIGHT SkipORT Multiplayer bruises Impact 2 is a conversation series that brings Amgen together with experts in patient advocacy and public health to discuss their shared values. IFPA, GHLF and Amgen have joined forces on the UPLIFT Innovation Program. IFP, GHF and amgen are working together to improve the patient care journey. Amgen Inc. has a strong focus on discovering, developing, and delivering innovative human therapeutics. In this chapter, we will examine the companys vision statement and explore each component, providing details to explain how Amgen aims to achieve its mission.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, AMGN, Health, Care, sector, industry, Therapeutics, and the most common words in the summary are: amgen, stock, inc, patient, amgn, year, program, . One of the sentences in the summary was: FTC first filed its lawsuit in May 2023, seeking to block Amgen.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #inc #patient #amgn #year #program.